Medical Pharmacology Chapter 33-34:  Anticancer Drugs

Previous Page Next Page

Section Table of Contents

Site Table of Contents

Previous Page Next Page

Section Table of Contents

Site Table of Contents

References
  1. Wellstein A Giaccone G Atkins MB Sausville Chapter 66:  Cytotoxic Drugs in Goodman & Gilman's:  The Pharmacological Basis of Therapeutics, 13e, Brunton LL Hilal-Dandan R Knollmann BC, eds) 2018.

  2. Sausville EA Longo DL Chapter 103e Principles of Cancer Treatment, in Harrison's Online   (Dennis L. Kasper, Anthony S. Fauci, Stephen L. Hauser, Dan L. Longo,  J. Larry Jameson, Joseph Loscalzo, Eds.),  Harrison's Principles of Internal Medicine, 19th edition, The McGraw-Hill Companies, Inc. 2015.

  3. Chu E  Cancer Chemotherapy Chapter 54 in Basic & Clinical Pharmacology, 14 e (Katzung BG The McGraw-Hill Companies, 2018 (on-line edition)

  4. Tew KD Chapter 17:  Alkylating Agents  in Principles & Practice of Oncology (DeVita, JR VT Lawrence TS Rosenberg SA, eds) 10e Wolters Kluwer Health 2015.

  5. Collins JM Cancer Pharmacology Chapter 29 in Abeloff's Clinical Oncology (Niederhuber JE Armitage JO Doroshow JH Kastan MB Tepper JE, eds)  5e Elsevier Churchill Livingstone, Philadelphia, PA 2014.

  6. Saif MW Chu E Chapter 19 Antimetabolites in Principles & Practice of Oncology (DeVita, JR VT Lawrence TS Rosenberg SA, eds) 10e Wolters Kluwer Health 2015.

  7. Wellstein A Giaccone G Atkins MB Sausville Chapter 67:  Pathway-Targeted Therapies:  Monoclonal Antibodies, Protein Kinase Inhibitors, and Various Small Molecules in Goodman & Gilman's:  The Pharmacological Basis of Therapeutics, 13e, Brunton LL Hilal-Dandan R Knollmann BC, eds) 2018.

  8. Chau CH Figg WD Chabner BA Antimitiotic Drugs Chapter 11 in:  Cancer Chemotherapy, Immunotherapy and Biotherapy Principles and Practice Chabner BA Longo DL, eds 6e Wolters Kluwer 2019.

  9. Hoimes CJ Chapter 24: Antimicrotubule Agents in Principles & Practice of Oncology (DeVita, JR VT Lawrence TS Rosenberg SA, eds) 11e Wolters Kluwer Health 2018.

  10. Descouens D Aril of the European yew 10 August 2012 https://commons.wikimedia.org/wiki/File:Taxus_baccata_MHNT.jpg

  11. Rosenstock AS Hortobagyi GN Chapter 27:  Early-Stage and Locally Advanced Breast Cancer in The MD Anderson Manual of Medical Oncology, 3e, 2016.

  12. Gomes DGD Gold KA Gibbons DL (Eapen GA, commentary) Chapter 18:  Non-Small Cell Lung Cancer in The MD Anderson Manual of Medical Oncology, 3e, 2016.

  13. Ross JS Ali SM Fasan O Black J Pal S Elvin JA Schrock AB Suh J Nozad S Kim S Lee HJ Sheehan CE Jones DM Vergillo J-A Ramkissoon S Severson E Daniel S Fabrizio D Frampton F Miller VA Stephens PJ Gay LM Alk Fusions in a Wide Variety of TUmor Types Respond to Anti-ALK Targeted Therapy Oncologiest 22(12) 1444-1450 Dec. 2017. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728036/

  14. ALK:  A Specific Oncogenic Driver. Genetech Biooncology https://www.biooncology.com/pathways/cancer-tumor-targets/alk/what-is-alk.html

  15. ROS1 https://en.wikipedia.org/wiki/ROS1

  16. ROS1:  A Driver of NSCLC Oncogenesis. Genentech Biooncology https://www.biooncology.com/pathways/cancer-tumor-targets/ros1/what-is-ros1.html

  17. Davies KD Doebele RC Molecular pathways:  Ros1 fusion proteins in cancer Clin Cancer Res 19(15); 4040-4045 Aug 1 2013 (second sourced from referenced 16). https://www.ncbi.nlm.nih.gov/pubmed/23719267

  18. Davies KD Le AT Theodoro MF Skokan MC Aisner DL Berge EM Terracciano LM Cappuzzo F Incarbone M Roncalli M Alloisio M Santoro A Camidge DF Valelia-Garcia M Doebele RC Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.  Clin Cancer Res 18(17); 4570-4579, Sept. 1, 2012. https://www.ncbi.nlm.nih.gov/pubmed/22919003 (second sourced from referenced 16).

  19. Morgan GJ He J Tytarenko R Patel P OW S Zhong S Deshpande S Bauer M Weinhold N Schinke C Rasche L Bailey M Ali S Ross J Miller VA Stephens P Thanendrarajan S Zangari M van Rhee F Mughal T Davies FE Walker BA Kinase domain activation through gene rearrangement in multiple myeloma. Leukemia 32(11):  2435-2444; Nov, 2018. https://www.ncbi.nlm.nih.gov/pubmed/29654269 (second sourced from referenced 16).

  20. Xhu YC Lin XP Li XF Wu LX Chen HF Wang WX Xu CW Shen JF Wei JG DU KQ Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma:  A case report and literature review.  Thorac Cancer 9(1); 159-163; Jan 2018. https://www.ncbi.nlm.nih.gov/pubmed/28971587 (second sourced from referenced 16).

  21. Vansteenkiste J Current status of adjuvant therapy for NSCLC. 17th Perspectives in Lung Cancer;  Prague March 2016. ImedexCME, published March 23, 2016 https://www.youtube.com/watch?v=E3zoO3KHF-M

This Web-based pharmacology teaching site is based on reference materials, that are believed reliable and consistent with standards accepted at the time of development. Possibility of human error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete. Users should confirm the information contained herein with other sources. This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site. Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals. Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.  Advertisements that appear on this site are not reviewed for content accuracy and it is the responsibility of users of this website to make individual assessments concerning this information.  Medical or other information  thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.